Drug class
Selective sodium-glucose cotransporter 2 (SGLT2) inhibitor; oral antihyperglycaemic
Mechanism of action
Inhibits SGLT2 in the proximal renal tubule, reducing filtered glucose reabsorption and increasing urinary glucose excretion, thereby lowering blood glucose.
General use cases
- Adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus under the US FDA human-product indication; not for type 1 diabetes or treatment of diabetic ketoacidosis
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
